
Opinion|Videos|December 18, 2024
Case 3: Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
Key Takeaways
Panelists discuss how the management of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence involves careful monitoring and the potential use of novel therapies, such as androgen receptor inhibitors, to delay progression and improve patient outcomes.
Advertisement
Episodes in this series
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Annual ACS NCDB report details national trends in prostate cancer care
2
FDA provides guidance on development pathway for testosterone therapy for women
3
Docetaxel plus tumor-targeting IL-12 yields promising activity in mCRPC
4
Treatment Selection in Advanced Prostate Cancer
5


